For US residents only.

How Treatment May Help

TAFINLAR + MEKINIST

Select an option to look at TAFINLAR + MEKINIST clinical trial results

Select an option to look at TAFINLAR + MEKINIST clinical trial results

Select an option to look at TAFINLAR + MEKINIST clinical trial results

Tough on BRAF+ melanoma after surgery

TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets is a targeted therapy that can be used as adjuvant (after surgery) treatment of BRAF+ melanoma. Adjuvant treatment is additional therapy given after a primary treatment (such as surgery) to further decrease the risk that the disease will progress. Your health care provider may prescribe you TAFINLAR + MEKINIST to help prevent your melanoma from coming back after surgery.

 

Benefits of TAFINLAR + MEKINIST therapy after surgery

The risk of cancer returning after surgery was reduced by more than 50%.*

Cancer-free after surgery

More patients treated with TAFINLAR + MEKINIST remained cancer-free after 12 months of treatment*

*As demonstrated by a clinical trial that included 870 patients with BRAF V600E or V600K mutation-positive stage III melanoma that was previously removed by surgery. Patients were treated with a combination of TAFINLAR + MEKINIST or placebo for 12 months. The numbers listed above were taken from the first check-in, at which at least half of the patients had been monitored for 2.8 years.

Tough on BRAF+ advanced melanoma

TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets is a targeted therapy that can be used as treatment for BRAF+ metastatic or inoperable melanoma. Your health care provider may prescribe you TAFINLAR + MEKINIST to help slow the progression of your melanoma if you have tested positive for BRAF melanoma.

 

Benefits of TAFINLAR + MEKINIST therapy for advanced melanoma

TAFINLAR + MEKINIST may offer a chance to extend your life*

Patients taking TAFINLAR + MEKINIST lived significantly longer than patients taking TAFINLAR*

About half of patients taking each treatment were alive after:

Patients lived longer without their disease worsening with TAFINLAR + MEKINIST*

About half of patients taking each treatment were alive without their disease worsening after:

More patients had their tumors shrink or disappear (known as the overall response rate) with TAFINLAR + MEKINIST*

  • Tumors disappeared completely in 10% of patients taking TAFINLAR + MEKINIST and 8% of patients taking TAFINLAR
  • Tumors shrank in 56% of patients taking TAFINLAR + MEKINIST and 42% of patients taking TAFINLAR
  • Tumors shrunk or disappeared for an average of 9.2 months with TAFINLAR + MEKINIST and 10.2 months with TAFINLAR

*As demonstrated by a clinical trial that included 423 adult patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma. Patients were treated with a combination of TAFINLAR + MEKINIST or TAFINLAR alone.